Camtek Receives Buy Rating from B. Riley (CAMT)

Share on StockTwits

Camtek (NASDAQ:CAMT)‘s stock had its “buy” rating restated by analysts at B. Riley in a research report issued to clients and investors on Wednesday. They currently have a $5.00 target price on the stock, up from their previous target price of $4.50. B. Riley’s price target suggests a potential upside of 34.77% from the company’s current price.

Shares of Camtek (NASDAQ:CAMT) traded down 0.27% during mid-day trading on Wednesday, hitting $3.70. The stock had a trading volume of 107,741 shares. Camtek has a one year low of $1.60 and a one year high of $6.43. The stock’s 50-day moving average is $3.56 and its 200-day moving average is $3.76. The company has a market cap of $112.7 million and a P/E ratio of 74.20.

Camtek (NASDAQ:CAMT) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.04. The company had revenue of $23.20 million for the quarter, compared to the consensus estimate of $23.15 million. During the same quarter in the previous year, the company posted $0.03 earnings per share. On average, analysts predict that Camtek will post $0.14 earnings per share for the current fiscal year.

Camtek Limited (NASDAQ:CAMT) designs, develops, manufactures and markets automated optical inspection (AOI), systems and related products.

Receive News & Ratings for Camtek Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Camtek Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Washington Real Estate Investment Trust Given Consensus Rating of “Hold” by Brokerages
Washington Real Estate Investment Trust Given Consensus Rating of “Hold” by Brokerages
Qunar Cayman Islands Receives Consensus Rating of “Buy” from Analysts
Qunar Cayman Islands Receives Consensus Rating of “Buy” from Analysts
Neurocrine Biosciences Given Average Rating of “Buy” by Brokerages
Neurocrine Biosciences Given Average Rating of “Buy” by Brokerages
Astoria Financial Corp Given Consensus Recommendation of “Hold” by Analysts
Astoria Financial Corp Given Consensus Recommendation of “Hold” by Analysts
KBR Receives Average Recommendation of “Buy” from Analysts
KBR Receives Average Recommendation of “Buy” from Analysts
Vanguard Natural Resources Given Consensus Recommendation of “Hold” by Analysts
Vanguard Natural Resources Given Consensus Recommendation of “Hold” by Analysts


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 Mideast Time.